Incyte Corporation (INCY) Shares are Down -6.1%

Incyte Corporation (INCY) : During the past 4 weeks, traders have been relatively bearish on Incyte Corporation (INCY), hence the stock is down -12.26% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -6.07% relative to the S&P 500. The 4-week change in the price of the stock is -11.92% and the stock has fallen -6.1% in the past 1 week.

Incyte Corporation has dropped 1.98% during the last 3-month period . Year-to-Date the stock performance stands at -29.82%. The stock has recorded a 20-day Moving Average of 10.92% and the 50-Day Moving Average is 8.1%.


Incyte Corporation (NASDAQ:INCY): The stock opened at $75.69 on Friday but the bulls could not build on the opening and the stock topped out at $77.65 for the day. The stock traded down to $75.52 during the day, due to lack of any buying support eventually closed down at $76.11 with a loss of -0.07% for the day. The stock had closed at $76.16 on the previous day. The total traded volume was 1,146,796 shares.

Also, Major Brokerage house, Barclays maintains its ratings on Incyte Corporation (NASDAQ:INCY). In the latest research report, Barclays raises the target price from $85 per share to $100 per share. According to the latest information available, the shares are now rated Overweight by the analysts at the agency. The rating by the firm was issued on August 10, 2016.

Incyte Corporation is a biopharmaceutical company focused on the discovery development and commercialization of small molecule drugs to treat serious unmet medical needs. The Companys compound JAKAFI (ruxolitinib) also known as INCB18424 and INC424 is an oral Janus associated kinase (JAK) inhibitor used for the treatment for patients with intermediate or highrisk myelofibrosis (MF) including primary MF postpolycythemia vera MF and postessential thrombocythemia MF. The Company has a second oral JAK1 and JAK2 inhibitor LY3009104 (INCB28050) , which is subject to a collaboration agreement with Eli Lilly and Company in , which Lilly received development and commercialization rights f

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *